Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company developing therapies for serious, rare skin diseases and vascular malformations, with plans to commercialize products if approved. Its proprietary QTORIN platform is designed to deliver topical drugs into the deeper layers of skin… From the company’s description.
In fiscal 2025, Palvella Therapeutics, Inc. reported a net loss of $41.72M. Operations used $25.01M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Palvella Therapeutics, Inc. does
In the company’s own words
Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company developing therapies for serious, rare skin diseases and vascular malformations, with plans to commercialize products if approved. Its proprietary QTORIN platform is designed to deliver topical drugs into the deeper layers of skin with limited systemic absorption. The lead candidate, QTORIN rapamycin, is in clinical development for microcystic lymphatic malformations and cutaneous venous malformations, with development also extending to clinically significant angiokeratomas. QTORIN pitavastatin is being developed for disseminated superficial actinic porokeratosis, and the company has additional preclinical programs. Palvella serves patients with these conditions and the clinicians who treat them; its proposed U.S. commercialization approach centers on specialty sales targeting vascular anomaly centers, dermatologists and other relevant specialists. The company’s business became primarily that of Legacy Palvella following its December 2024 merger with Pieris Pharmaceuticals, which then adopted the Palvella name. Its website is www.palvellatherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WAYNE, PA
- Fiscal year end
- December
- CIK
- 1583648
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Palvella Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Palvella Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Palvella Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Palvella Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Palvella Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”